Health ❯ Healthcare ❯ Pharmaceuticals ❯ Drug Development

Alzheimer's Disease

FDA Approves At-Home Starter Dose for Leqembi

The move could expand access by letting patients begin subcutaneous injections at home after regulators accepted pharmacokinetic equivalence rather than new large outcome trials.

3 ARTICLES

2mo ago

Neumora Halts Navacaprant After Phase 3 KOASTAL Failures

9 ARTICLES

3mo ago

Lilly Launches First Amyloid-Targeting Alzheimer’s Drug in India at Rs 91,688 a Dose

4 ARTICLES

6mo ago

FDA Grants Priority Review to Leqembi Autoinjector for Weekly At-Home Starting Dose

4 ARTICLES

7mo ago

Novartis Licenses SciNeuro’s Brain‑Shuttle Alzheimer’s Antibodies in Deal Worth Up to $1.7 Billion

59 ARTICLES

8mo ago

Novo Nordisk’s Oral Semaglutide Fails to Slow Alzheimer’s in Dual Phase 3 Trials

4 ARTICLES

9mo ago

UK Approves Once-Every-Four-Weeks IV Maintenance Dosing for Leqembi in Early Alzheimer’s

8 ARTICLES

9mo ago

Health Canada Conditionally Authorizes First Alzheimer’s Drug to Slow Early Decline

5 ARTICLES

10mo ago

Australia Registers Alzheimer’s Drug Leqembi With APOE4-Based Restrictions

6 ARTICLES

11mo ago

FDA Clears At-Home Leqembi Injection for Weekly Maintenance in Early Alzheimer’s

5 ARTICLES

11mo ago

Alzheimer Drug Leqembi Launches in Germany and Austria on September 1 Under Strict Conditions

5 ARTICLES

last yr.

NHS Declines Coverage for Groundbreaking Alzheimer's Drug Due to High Costs

Alzheimer's Disease

FDA Approves At-Home Starter Dose for Leqembi

Neumora Halts Navacaprant After Phase 3 KOASTAL Failures

Lilly Launches First Amyloid-Targeting Alzheimer’s Drug in India at Rs 91,688 a Dose

FDA Grants Priority Review to Leqembi Autoinjector for Weekly At-Home Starting Dose

Novartis Licenses SciNeuro’s Brain‑Shuttle Alzheimer’s Antibodies in Deal Worth Up to $1.7 Billion

Novo Nordisk’s Oral Semaglutide Fails to Slow Alzheimer’s in Dual Phase 3 Trials

UK Approves Once-Every-Four-Weeks IV Maintenance Dosing for Leqembi in Early Alzheimer’s

Health Canada Conditionally Authorizes First Alzheimer’s Drug to Slow Early Decline

Australia Registers Alzheimer’s Drug Leqembi With APOE4-Based Restrictions

FDA Clears At-Home Leqembi Injection for Weekly Maintenance in Early Alzheimer’s

Never miss stories about

Alzheimer's Disease

Alzheimer Drug Leqembi Launches in Germany and Austria on September 1 Under Strict Conditions

EMA Recommends Restricted Approval for Eli Lilly’s Alzheimer’s Drug Kisunla

NICE Bars New Alzheimer’s Antibodies from NHS Over Cost and Capacity

NICE Poised to Reject NHS Coverage for Breakthrough Alzheimer’s Drugs

Australia Approves Donanemab as First Disease-Modifying Alzheimer’s Therapy

EU Approves First Alzheimer's Drug Targeting Disease Progression

EMA Approves Lecanemab for Early-Stage Alzheimer’s Treatment in EU

NHS Rejects Alzheimer’s Drug Donanemab Despite Promising Results

NHS Declines Coverage for Groundbreaking Alzheimer's Drug Due to High Costs

Never miss stories about

Alzheimer's Disease